Research for treatments, prevention and a cure
Page template: single-clinical-trials.php
Search terms : 

Clinical Trials

  • Clinical Studies

Clinical Management Science (CMS)

CTNPT 008: HIV quit smoking pilot study

Trial results

Print Friendly, PDF & Email


The rates of cardiovascular disease (CVD) are high among people living with HIV. Two of the factors thought to contribute to this inflated risk are increased smoking rates and the prevalence of depression in people living with HIV. Smoking is a direct risk factor for CVD and depression makes quitting smoking and remaining smoke-free more difficult. Therefore, the increase in depression and smoking rates may interact to increase the rates of CVD in people living with HIV. CTNPT 008 looked at the effectiveness of a counselling programme, in combination with nicotine replacement therapy (nicotine patch) to improve quitting rates. The counselling sessions focused on quitting smoking and addressing depression.

Study Population

Fifty participants were recruited from the Ottawa Hospital. Participants had to be a current smoker, willing to quit within 30 days, diagnosed with HIV, and currently on antiretroviral therapy.

Study Design

The study used a 24-week counselling design with a 6-month follow up. Counselling sessions occurred at baseline, quit date, and 4, 12, and 24 weeks after quitting. Abstinence from smoking was assessed using self-report questionnaires and biochemical measurement (exhaled carbon monoxide). Psychological and physiological measurements were repeated 6 months following the 24-week counselling period. Study participants were also given telephone-based support throughout the counselling period.

Results and Conclusions

At 6-month follow-up, 28% of participants demonstrated biochemically verified abstinence from smoking. This is considered a successful smoking intervention and compares well to other similar studies. At baseline, 52% of study participants showed signs of clinical depression. At 6-month follow-up, there was a trend towards a decrease in depression. Those with depression were not more likely to relapse back to smoking. This highlights the importance of including depression in counselling sessions to address this barrier to stopping smoking successfully. This pilot trial showed the importance of this type of program to help people with HIV quit smoking. 

Additional Information

Principal investigator

Dr. Louise Balfour
Ottawa Hospital and the University of Ottawa


Balfour L, Wiebe SA, Cameron WD, Sandre D, Pipe A, Cooper C, Angel J, Garber G, Holly C, Dalgleish TL, Tasca GA, MacPherson PA. An HIV-tailored quit-smoking counselling pilot intervention targeting depressive symptoms plus Nicotine Replacement Therapy. AIDS Care. 2017 Jan;29(1):24-31. Epub 2016 Jul 19.

Latest News

In Memoriam: Dr. David Cooper

| Uncategorized | No Comments

The CTN offers condolences to the family, friends, and colleagues of Dr. David Cooper. Dr. Cooper dedicated his life to…

Trans Working Group Working To Remove Health Care Barriers

| Uncategorized | No Comments

  The Prevention and Vulnerable Populations (PVP) Core’s Trans Working Group has submitted their first grant proposal. The proposal is…

Canadian Guidelines on PrEP and nPEP Published

| Uncategorized | No Comments

After nearly two years of work and consultation, the first Canadian Guidelines on pre-exposure prophylaxis (PrEP) and non-occupational post-exposure prophylaxis…

Why do we need PrEP Guidelines? Ask an expert. VIDEO

| Uncategorized | No Comments

Despite efforts to reduce new incidences of HIV like condom campaigns, needle exchanges, and treatment as prevention, the actual number…

Research for treatments, prevention and a cure